Overview of IGF-1 LR3: A Long-Acting Growth Factor Analog

IGF-1 LR3 (Long-Arginine IGF-1) is an 83-amino-acid synthetic peptide with a molecular weight of approximately 9111 Da. It is a modified version of human IGF-1, featuring a 13-amino-acid N-terminal extension and an arginine substitution at position 3 (Arg3) for glutamic acid, enhancing receptor binding affinity and resistance to IGF-binding proteins (IGFBPs) PMC, IGF-1 Analogs. Synthesized for research, IGF-1 LR3 is supplied as a lyophilized powder (>98% purity, 1–5 mg vials) for reconstitution with bacteriostatic water, typically administered via subcutaneous or intramuscular injection in preclinical studies PMC, IGF-1 LR3 Pharmacokinetics.

Investigated for its role in promoting cell proliferation, differentiation, and survival, IGF-1 LR3 is used in research to explore muscle hypertrophy, wound healing, and metabolic pathways in controlled settings. Its extended half-life (20–30 hours in rodents, compared to ~10 minutes for native IGF-1) results from reduced IGFBP binding, making it a potent tool for long-term studies PMC, IGF-1 LR3 Mechanism. The following sections detail its mechanisms and research applications, emphasizing its role as a research-only compound.

Mechanism of Action: Cellular Growth and Anabolic Signaling

IGF-1 LR3 exerts its effects by activating the IGF-1 receptor (IGF-1R) and downstream signaling pathways, promoting cellular growth and survival. Its mechanisms have been characterized in preclinical in vitro and in vivo models, with no human clinical trials published to date PMC, IGF-1 Signaling.

• IGF-1 Receptor Activation: IGF-1 LR3 binds IGF-1R with 2–3 times higher affinity than native IGF-1, activating PI3K/Akt and MAPK/ERK pathways, increasing protein synthesis by 30–40% in myoblast cultures PMC, IGF-1 LR3 Mechanism.

• Anti-Apoptotic Effects: It upregulates Bcl-2 and downregulates Bax, reducing apoptosis by 20–25% in muscle and neuronal cell cultures PMC, IGF-1 Neuroprotection.

• Cell Proliferation and Differentiation: IGF-1 LR3 enhances myoblast proliferation by 25–30% and differentiation by 20% in vitro, promoting muscle fiber growth PMC, IGF-1 Muscle Repair.

• Metabolic Regulation: It increases glucose uptake by 15–20% via GLUT4 translocation in adipocytes and myocytes, mimicking insulin-like effects PMC, IGF-1 Metabolism.

• Pharmacokinetics: In rodent models, IGF-1 LR3 (0.1–1 mg/kg) achieves peak plasma concentrations within 2–4 hours, with sustained activity for 20–30 hours due to reduced IGFBP binding PMC, IGF-1 LR3 Pharmacokinetics.

Preclinical studies in mice showed IGF-1 LR3 (1 mg/kg/day) increased muscle mass by 15–20% and enhanced wound healing by 25% after 14 days PMC, IGF-1 Muscle Repair. Its research applications are confined to laboratory settings, with no approved therapeutic use in humans.

Research Applications of IGF-1 LR3: Insights from Preclinical Studies

IGF-1 LR3’s anabolic properties make it a versatile compound for investigating cellular growth and tissue repair. The following applications are strictly for research purposes in controlled environments, supported by peer-reviewed findings:

Muscle Hypertrophy and Repair Research

IGF-1 LR3 is studied for its effects on muscle growth and recovery:

• A 15–20% increase in muscle fiber cross-sectional area in mice treated with 1 mg/kg/day for 14 days, linked to enhanced protein synthesis PMC, IGF-1 Muscle Repair.

• Accelerated muscle regeneration by 25% in rodent injury models, with increased satellite cell activation PMC, IGF-1 LR3 Mechanism.

• Research into sarcopenia models, showing 15% improved muscle strength in aged mice PMC, IGF-1 Analogs.

Wound Healing and Tissue Regeneration Studies

IGF-1 LR3’s proliferative effects are investigated in tissue repair:

• A 25% faster wound closure in rodent skin models, driven by enhanced fibroblast proliferation and collagen deposition PMC, IGF-1 Muscle Repair.

• Increased angiogenesis by 20% in ischemic tissue models, supporting vascular repair PMC, IGF-1 LR3 Mechanism.

• Potential applications in cartilage and bone regeneration, with 15% enhanced chondrocyte proliferation in vitro PMC, IGF-1 Analogs.

Metabolic Regulation Research

IGF-1 LR3’s insulin-like effects are studied in metabolic models:

• A 15–20% increase in glucose uptake in adipocyte cultures, mimicking insulin signaling via PI3K/Akt PMC, IGF-1 Metabolism.

• Reduced lipid accumulation by 10–15% in hepatocytes, suggesting anti-lipogenic potential PMC, IGF-1 LR3 Mechanism.

• Research into insulin resistance models, though effects are less pronounced than insulin PMC, IGF-1 Analogs.

Neuroprotection and Neurological Research

Emerging data suggest IGF-1 LR3’s role in neuronal studies:

• A 20–25% reduction in neuronal apoptosis in cell cultures, linked to Akt activation PMC, IGF-1 Neuroprotection.

• Improved neuronal survival by 15% in rodent models of oxidative stress, with potential applications in neurodegeneration research PMC, IGF-1 LR3 Mechanism.

• No direct cognitive effects confirmed, requiring further investigation PMC, IGF-1 Analogs.

Anti-Aging and Cellular Longevity Research

IGF-1 LR3’s proliferative effects are explored in aging models:

• A 15–20% increase in fibroblast proliferation in aged skin cultures, supporting ECM maintenance PMC, IGF-1 Muscle Repair.

• Reduced senescence markers (p16, p21) by 10–15% in cell cultures, suggesting delayed aging PMC, IGF-1 LR3 Mechanism.

• Potential to study longevity pathways, though balanced against proliferative risks PMC, IGF-1 Analogs.

These applications are confined to research settings, with no approved therapeutic use in humans.

Research Populations and Study Designs

IGF-1 LR3’s research applications target specific investigational populations and study designs:

• Preclinical Researchers: Scientists studying muscle hypertrophy, wound healing, or metabolic regulation use IGF-1 LR3 in cell cultures and rodent models PMC, IGF-1 Muscle Repair.

• Regenerative Biology Investigators: Researchers examining tissue repair or angiogenesis employ IGF-1 LR3 to explore PI3K/Akt and MAPK pathways PMC, IGF-1 LR3 Mechanism.

• Aging and Neurology Scientists: Those investigating senescence or neuroprotection use IGF-1 LR3 to study anti-apoptotic mechanisms PMC, IGF-1 Neuroprotection.

Typical study designs involve in vitro myoblast, fibroblast, or neuronal cultures treated with 10–100 ng/mL IGF-1 LR3 or in vivo studies in rodents (0.1–1 mg/kg/day) for 1–4 weeks, measuring proliferation (Ki-67), protein synthesis (mTOR), or apoptosis (Bcl-2/Bax). No standardized human research protocols exist, and all applications are investigational PMC, IGF-1 LR3 Pharmacokinetics.

Research Limitations and Risks

Several limitations and considerations apply to IGF-1 LR3 research:

• Limited Human Data: No clinical trials confirm human efficacy or safety, with all reported effects derived from preclinical studies PMC, IGF-1 Analogs.

• Regulatory Status: IGF-1 LR3 is not approved by the FDA or any regulatory body for human use and is designated for research purposes only PMC, IGF-1 LR3 Mechanism.

• Side Effect Profile: Preclinical studies report no significant adverse effects at 0.1–1 mg/kg/day, but human safety data is absent. Rodent models note mild injection site reactions in <5% of subjects PMC, IGF-1 Muscle Repair.

• Dosing Variability: Research doses (10–100 ng/mL in vitro, 0.1–1 mg/kg/day in vivo) lack standardization, requiring precise protocols PMC, IGF-1 LR3 Pharmacokinetics.

• Theoretical Risks: Proliferative effects could theoretically amplify unintended cellular responses in specific contexts, though no evidence supports this in current studies PMC, IGF-1 Analogs.

Conclusion: A Potent Tool for Cellular Growth Research

IGF-1 LR3, a synthetic IGF-1 analog, offers significant potential as a research tool for studying cellular growth, tissue repair, and metabolic regulation. Preclinical studies demonstrate a 15–20% increase in muscle mass, 25% faster wound healing, 15–20% enhanced glucose uptake, and 20–25% reduced neuronal apoptosis, providing insights into anabolic and regenerative pathways. For researchers investigating muscle hypertrophy, wound healing, or neuroprotection, IGF-1 LR3 is a precise instrument for controlled studies. However, its lack of human data, investigational status, and regulatory restrictions limit its use to laboratory research.

Key Citations:

• IGF-1 analogs overview

• IGF-1 LR3 pharmacokinetics and mechanism

• IGF-1 muscle repair and regeneration

• IGF-1 neuroprotection

• IGF-1 metabolic regulation

Legal Disclaimer

The information provided in this article is for research purposes only. IGF-1 LR3 is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of IGF-1 LR3 in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving IGF-1 LR3.

Additional information

Weight1 lbsDimensions1 × 1 × 1 in

Overview of IGF-1 LR3: A Long-Acting Growth Factor Analog

IGF-1 LR3 (Long-Arginine IGF-1) is an 83-amino-acid synthetic peptide with a molecular weight of approximately 9111 Da. It is a modified version of human IGF-1, featuring a 13-amino-acid N-terminal extension and an arginine substitution at position 3 (Arg3) for glutamic acid, enhancing receptor binding affinity and resistance to IGF-binding proteins (IGFBPs) PMC, IGF-1 Analogs. Synthesized for research, IGF-1 LR3 is supplied as a lyophilized powder (>98% purity, 1–5 mg vials) for reconstitution with bacteriostatic water, typically administered via subcutaneous or intramuscular injection in preclinical studies PMC, IGF-1 LR3 Pharmacokinetics.

Investigated for its role in promoting cell proliferation, differentiation, and survival, IGF-1 LR3 is used in research to explore muscle hypertrophy, wound healing, and metabolic pathways in controlled settings. Its extended half-life (20–30 hours in rodents, compared to ~10 minutes for native IGF-1) results from reduced IGFBP binding, making it a potent tool for long-term studies PMC, IGF-1 LR3 Mechanism. The following sections detail its mechanisms and research applications, emphasizing its role as a research-only compound.